3D Medicines (HKG:1244) appointed Ding Gan as the chief commercial officer, according to a Monday filing with the Hong Kong bourse.
Ding has more than 30 years of experience in the pharmaceutical and biotechnology industries, the filing added. He most recently served as served as the chief executive officer of Nicoya Therapeutics
(Shanghai) and Alternative Bio (ABio).
Price (HKD): $2.98, Change: $-0.020, Percent Change: -0.67%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.